NEW YORK (TheStreet) -- Teva Pharmaceuticals (TEVA - Get Report) rose Monday after the company unveiled its new organizational structure that trims the size of the executive committee and creates two commercial business units.
The company plans to combine its generic operations into group called Global Generic Medicines. Sigurdur Olafsson, who previously served as president of Actavis PLC, will serve as president and chief executive of the unit. The other group will be Global Specialty Medicines, formed in April 2013. The organizational restructuring also cuts the size of Teva's executive committee from 15 members to 9.
The changes become effective July 1 and the company intends them to provide "seamless global integration, focus and effectiveness across the company," according to Teva's press release.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. The stock was up 2.61% to $51.81 at 12:08 p.m. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts